Toronto

Az itteni vizsgálatok

Miről szól a helyszín 176 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák33 vizsgálat
• Prosztatarák12 vizsgálat
• Gyomor- és nyelőcsőrák11 vizsgálat
• Áttétes emlőrák10 vizsgálat
• Máj- és epeúti rák10 vizsgálat
• Petefészekrák10 vizsgálat
• 2-es típusú cukorbetegség9 vizsgálat
• Elhízás8 vizsgálat
• Asztma7 vizsgálat
• Hólyagrák7 vizsgálat
• Méhtestrák7 vizsgálat
• Amiloidózis6 vizsgálat
• és még 40

Fázis

• 3. fázis113 vizsgálat
• 2. fázis27 vizsgálat
• 1/2. fázis19 vizsgálat
• 1. fázis7 vizsgálat
• 2/3. fázis2 vizsgálat
• 4. fázis2 vizsgálat

Állapot

• Fut, nem toboroz81 vizsgálat
• Toboroz39 vizsgálat
• Lezárult33 vizsgálat
• Még nem toboroz11 vizsgálat
• Visszavonták8 vizsgálat
• Leállították3 vizsgálat
• Felfüggesztve1 vizsgálat

Fő szponzor

• AstraZeneca148 vizsgálat
• Alexion Pharmaceuticals, Inc.11 vizsgálat
• Acerta Pharma BV5 vizsgálat
• Arcus Biosciences, Inc.4 vizsgálat
• MedImmune LLC3 vizsgálat
• és még 5

Futó vizsgálatok

• Toboroz

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

  NCT07619118· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· 3. fázis· AstraZeneca· Forrás

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Toboroz

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  NCT07784270· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  NCT07444567· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

  NCT07664553· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  NCT07509151· 3. fázis· AstraZeneca· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  NCT07430306· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  NCT07109219· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

  NCT07192614· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· 3. fázis· Arcus Biosciences, Inc.· Forrás

  Contact: Medical Director

• Toboroz

  LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

  NCT07143110· AstraZeneca· Forrás

• Toboroz

  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

  NCT06897930· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

  NCT06512883· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· AstraZeneca· Forrás

• Toboroz

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

  NCT06792695· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Fut, nem toboroz

  A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

  NCT06700538· 1/2. fázis· Arrowhead Pharmaceuticals· Forrás

• Toboroz

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· AstraZeneca· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· 3. fázis· AstraZeneca· Forrás

• Toboroz

  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  NCT05835310· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

Showing 50 of 131.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák6 toboroz
• 2-es típusú cukorbetegség5 toboroz
• Lupus (SLE)4 toboroz
• Máj- és epeúti rák4 toboroz
• Elhízás3 toboroz
• Follikuláris limfóma3 toboroz
• Gyermekkori daganatok3 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Krónikus vesebetegség3 toboroz
• Méhtestrák3 toboroz
• Petefészekrák3 toboroz
• Prosztatarák3 toboroz
• Szívelégtelenség3 toboroz
• Akut limfoid leukémia (ALL)2 toboroz
• ANCA-asszociált vasculitis2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Mielóma multiplex2 toboroz
• 1-es típusú cukorbetegség1 toboroz
• Amiloidózis1 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hodgkin-limfóma1 toboroz
• Köpenysejtes limfóma1 toboroz
• Koszorúér-betegség1 toboroz
• Magas vérnyomás1 toboroz
• Méhnyakrák1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz
• Tripla negatív emlőrák1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Toboroz

  A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  NCT07776509· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  NCT07081646· 1/2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Toboroz

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  NCT07069712· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

  NCT06579105· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

  NCT06579092· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

  NCT06595238· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus

  NCT06485674· AstraZeneca· Forrás

• Toboroz

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

  NCT05938270· 1. fázis· AstraZeneca· Forrás

• Lezárult

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· 2. fázis· AstraZeneca· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

  NCT05755906· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

  NCT05677139· AstraZeneca· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Toboroz

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  NCT05489211· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

  NCT05329766· 2. fázis· Arcus Biosciences, Inc.· Forrás

• Leállították

  Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

  NCT05218096· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT05216835· 1. fázis· AstraZeneca· Forrás

• Lezárult

  A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

  NCT05202262· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· 2/3. fázis· AstraZeneca· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· 4. fázis· AstraZeneca· Forrás

• Lezárult

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

  NCT04610892· 2. fázis· AstraZeneca· Forrás

• Lezárult

  First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

  NCT04504669· 1. fázis· AstraZeneca· Forrás

• Lezárult

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· 4. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

  NCT03976349· 1. fázis· Ionis Pharmaceuticals, Inc.· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

  NCT03833141· AstraZeneca· Forrás

• Lezárult

  Long-Term Evaluation of BIIB067 (Tofersen)

  NCT03070119· 3. fázis· Biogen· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

  NCT02094261· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

  NCT01226316· 1. fázis· AstraZeneca· Forrás